Page 14 - 《中国药科大学学报》2025年第5期

546 学报 Journal of China Pharmaceutical University 2025, 56(5): 539 − 547 第 56 卷

[32] Lee H, Kim J, Choi Y, et al. Application of gelatin bioinks and drug clearance with a human microfluidic four-cell liver acinus
cell-printing technology to enhance cell delivery capability for microphysiology system[J]. Toxicology, 2021, 463: 152954.
3D liver fibrosis-on-a-chip development[J]. ACS Biomater Sci [48] Docci L, Milani N, Ramp T, et al. Exploration and application
Eng, 2020, 6(4): 2469-2477. of a liver-on-a-chip device in combination with modelling and
[33] Liu T, Ge YQ, Chen ZP, et al. Synergistic modulation of a tun- simulation for quantitative drug metabolism studies[J]. Lab
able microenvironment to fabricate a liver fibrosis chip for drug Chip, 2022, 22(6): 1187-1205.
testing[J]. ACS Biomater Sci Eng, 2023, 9(8): 4893-4906. [49] Ouattara DA, Choi SH, Sakai Y, et al. Kinetic modelling of in
[34] Kang Y, Rawat S, Duchemin N, et al. Human liver sinusoid on vitro cell-based assays to characterize non-specific bindings and
a chip for hepatitis B virus replication study[J]. Micromachines, ADME processes in a static and a perfused fluidic system[J].
2017, 8(1): 27. Toxicol Lett, 2011, 205(3): 310-319.
[35] Ortega-Prieto AM, Skelton JK, Wai SN, et al. 3D microfluidic
[50] Tsamandouras N, Kostrzewski T, Stokes CL, et al. Quantitative
liver cultures as a physiological preclinical tool for hepatitis B assessment of population variability in hepatic drug metabolism
virus infection[J]. Nat Commun, 2018, 9(1): 682.
using a perfused three-dimensional human liver microphysio-
[36] Deguchi S, Kosugi K, Hashimoto R, et al. Elucidation of the
logical system[J]. J Pharmacol Exp Ther, 2017, 360(1): 95-105.
liver pathophysiology of COVID-19 patients using liver-on-a-
[51] Busche M, Tomilova O, Schütte J, et al. HepaChip-MP–a twen-
chips[J]. PNAS Nexus, 2023, 2(3): pgad029.
ty-four chamber microplate for a continuously perfused liver co-
[37] Negi V, Gavlock D, Miedel MT, et al. Modeling mechanisms
culture model[J]. Lab Chip, 2020, 20(16): 2911-2926.
underlying differential inflammatory responses to COVID-19 in
[52] Kwon D, Choi G, Park SA, et al. Liver acinus dynamic chip for
type 2 diabetes using a patient-derived microphysiological or-
assessment of drug-induced zonal hepatotoxicity[J]. Biosensors
gan-on-a-chip system[J]. Lab Chip, 2023, 23(20): 4514-4527.
(Basel), 2022, 12(7): 445.
[38] Wang MY, Sasaki Y, Sakagami R, et al. Perfluoropolyether-
[53] Jang KJ, Otieno MA, Ronxhi J, et al. Reproducing human and
based gut-liver-on-a-chip for the evaluation of first-pass
cross-species drug toxicities using a Liver-Chip[J]. Sci Transl
metabolism and oral bioavailability of drugs[J]. ACS Biomater
Med, 2019, 11(517): eaax5516.
Sci Eng, 2024, 10(7): 4635-4644.
[54] Ehrlich A, Tsytkin-Kirschenzweig S, Ioannidis K, et al. Micro-
[39] De Gregorio V, Telesco M, Corrado B, et al. Intestine-liver ax-
physiological flux balance platform unravels the dynamics of
is on-chip reveals the intestinal protective role on hepatic dam-
drug induced steatosis[J]. Lab Chip, 2018, 18(17): 2510-2522.
age by emulating ethanol first-pass metabolism[J]. Front Bio-
[55] Gehre C, Flechner M, Kammerer S, et al. Real time monitoring
eng Biotechnol, 2020, 8: 163.
of oxygen uptake of hepatocytes in a microreactor using optical
[40] Kimura H, Ikeda T, Nakayama H, et al. An on-chip small intes-
microsensors[J]. Sci Rep, 2020, 10(1): 13700.
tine-liver model for pharmacokinetic studies[J]. J Lab Autom,
[56] Levner D, Ewart L. Integrating Liver-Chip data into pharmaceu-
2015, 20(3): 265-273.
tical decision-making processes[J]. Expert Opin Drug Discov,
[41] Chen PY, Hsieh MJ, Liao YH, et al. Liver-on-a-chip platform to
2023, 18(12): 1313-1320.
study anticancer effect of statin and its metabolites[J]. Biochem
[57] Compiling Expert Group for Expert Consensus on Technical
Eng J, 2021, 165: 107831.
Specification of Human Liver-on-Chip for Evaluating Drug-In-
[42] Li ZY, Li D, Guo YQ, et al. Evaluation of hepatic drug-
duced Liver Injury. Expert consensus on technical specifica-
metabolism for glioblastoma using liver-brain chip[J]. Biotech-
tions for human liver-on-a-chip in the evaluation of drug-in-
nol Lett, 2021, 43(2): 383-392.
[43] Görgens C, Ramme AP, Guddat S, et al. Organ-on-a-chip: de- duced liver injury[J]. Chin J Biomed Eng 2024, 43(05): 513-
524.
termine feasibility of a human liver microphysiological model
to assess long-term steroid metabolites in sports drug testing[J]. [58] Ferrari E, Visone R, Monti E, et al. LivHeart: a multi organ-on-
Drug Test Anal, 2021, 13(11/12): 1921-1928. chip platform to study off-target cardiotoxicity of drugs upon
[44] Huang QH, Yang TH, Song YP, et al. A three-dimensional (3D) liver metabolism[J]. Adv Mater Technol, 2023, 8(8): 2201435.
liver–kidney on a chip with a biomimicking circulating system [59] Messelmani T, Morisseau L, Sakai Y, et al. Liver organ-on-chip
for drug safety evaluation[J]. Lab Chip, 2024, 24(6): 1715- models for toxicity studies and risk assessment[J]. Lab Chip,
1726. 2022, 22(13): 2423-2450.
[45] Lucchetti M, Aina KO, Grandmougin L, et al. An organ-on- [60] Rajan SAP, Aleman J, Wan MM, et al. Probing prodrug
chip platform for simulating drug metabolism along the gut-liv- metabolism and reciprocal toxicity with an integrated and hu-
er axis[J]. Adv Healthc Mater, 2024, 13(20): e2303943. manized multi-tissue organ-on-a-chip platform[J]. Acta Bio-
[46] Herland A, Maoz BM, Das D, et al. Quantitative prediction of mater, 2020, 106: 124-135.
human pharmacokinetic responses to drugs via fluidically cou- [61] Deng J, Zhang XL, Chen ZZ, et al. A cell lines derived mi-
pled vascularized organ chips[J]. Nat Biomed Eng, 2020, 4(4): crofluidic liver model for investigation of hepatotoxicity in-
421-436. duced by drug-drug interaction[J]. Biomicrofluidics, 2019,
[47] Sakolish C, Luo YS, Valdiviezo A, et al. Prediction of hepatic 13(2): 024101.